Literature DB >> 28153721

MiR-138 indirectly regulates the MDR1 promoter by NF-κB/p65 silencing.

J L Requenez-Contreras1, E S López-Castillejos1, R Hernández-Flores1, M A Moreno-Eutimio2, J T Granados-Riveron3, G U Martinez-Ruiz4, G Aquino-Jarquin5.   

Abstract

MicroRNAs (miRNAs) are known to mediate post-transcriptional gene silencing in the cytoplasm and recent evidence indicates that may also possess nuclear roles in regulating gene expression. A previous study showed that miR-138 is involved in the multidrug resistance of leukemia cells through down-regulation of the drug efflux pump P-glycoprotein (P-gp), the protein encoded by the human multidrug-resistant ABCB1/MDR1 gene. However, the transcriptional regulatory mechanisms responsible remain to be elucidated. To deepen the description of the mechanism of transcriptional gene silencing on the MDR1 promoter, we initially performed a bioinformatics search for potential miR-138 binding sites in the MDR1 gene promoter sequence. Interestingly, we did not find miR-138 binding sites in this region, suggesting an indirect regulation. From six representative transcriptional factors involved in MDR1 gene regulation, an in silico analysis revealed that NF-κB/p65 has a specific binding site for miR-138. The results of luciferase reporter assay, western blot and flow cytometry shown here suggest that miR-138 might modulate the human MDR1 expression by inhibiting NF-κB/p65 as an indirect mechanism of MDR1 regulation. Furthermore, employing the human macrophage-like cell line U937 we observed comparable results with NF-κB/p65 down-regulation and we also observed a significant reduction in the IL-6 and TNF-α mRNA, as well as in their secreted pro-inflammatory cytokines following miR-138 expression, suggesting that canonical NF-κB target genes might also be potential targets for miR-138 in leukemia cells.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Indirect mechanism; MDR1 promoter; NF-κB/p65 protein; RelA mRNA; miR-138

Mesh:

Substances:

Year:  2017        PMID: 28153721     DOI: 10.1016/j.bbrc.2017.01.168

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of β-catenin in prostate cancer cells.

Authors:  Kati Erdmann; Knut Kaulke; Christiane Rieger; Manfred P Wirth; Susanne Fuessel
Journal:  J Cancer Res Clin Oncol       Date:  2017-07-24       Impact factor: 4.553

Review 2.  The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Authors:  Mariana Medeiros; Marina Ferreira Candido; Elvis Terci Valera; María Sol Brassesco
Journal:  Cell Mol Life Sci       Date:  2021-07-31       Impact factor: 9.261

3.  Fascin promotes migration and invasion and is a prognostic marker for oral squamous cell carcinoma.

Authors:  Priscila Campioni Rodrigues; Iris Sawazaki-Calone; Carine Ervolino de Oliveira; Carolina Carneiro Soares Macedo; Mauricio Rocha Dourado; Nilva K Cervigne; Marcia Costa Miguel; Andreia Ferreira do Carmo; Daniel W Lambert; Edgard Graner; Sabrina Daniela da Silva; Moulay A Alaoui-Jamali; Adriana Franco Paes Leme; Tuula A Salo; Ricardo D Coletta
Journal:  Oncotarget       Date:  2017-08-19

4.  MicroRNA-298 Reverses Multidrug Resistance to Antiepileptic Drugs by Suppressing MDR1/P-gp Expression in vitro.

Authors:  Yangmei Xie; Yiye Shao; Xiaolin Deng; Ming Wang; Yinghui Chen
Journal:  Front Neurosci       Date:  2018-08-28       Impact factor: 4.677

5.  Nodal is involved in chemoresistance of renal cell carcinoma cells via regulation of ABCB1.

Authors:  Xingwang Zhu; Dongwei Xue; Jia Liu; Fengming Dong; Yongzhi Li; Yili Liu
Journal:  J Cancer       Date:  2021-02-02       Impact factor: 4.207

6.  Dexmedetomidine impairs P‑glycoprotein‑mediated efflux function in L02 cells via the adenosine 5'‑monophosphate‑activated protein kinase/nuclear factor‑κB pathway.

Authors:  Guo-Rong He; Xiao-Kun Lin; Yong-Biao Wang; Cong-De Chen
Journal:  Mol Med Rep       Date:  2018-02-02       Impact factor: 2.952

7.  Combination chemotherapy with Zyflamend reduced the acquired resistance of bladder cancer cells to cisplatin through inhibiting NFκB signaling pathway.

Authors:  Yanshi Xue; Jun Yan; Lin Yang; Junzun Li; Yilin Yan; Qinghui Jiang; Lan Shen; Shuai Yang; Bing Shen; Ruimin Huang; Hongqian Guo
Journal:  Onco Targets Ther       Date:  2018-07-30       Impact factor: 4.147

Review 8.  miRNA-based biomarkers, therapies, and resistance in Cancer.

Authors:  Boxue He; Zhenyu Zhao; Qidong Cai; Yuqian Zhang; Pengfei Zhang; Shuai Shi; Hui Xie; Xiong Peng; Wei Yin; Yongguang Tao; Xiang Wang
Journal:  Int J Biol Sci       Date:  2020-07-19       Impact factor: 6.580

9.  N6-methyladenosine-induced ERRγ triggers chemoresistance of cancer cells through upregulation of ABCB1 and metabolic reprogramming.

Authors:  Zhuojia Chen; Long Wu; Jiawang Zhou; Xinyao Lin; Yanxi Peng; Lichen Ge; Cheng-Ming Chiang; Hui Huang; Hongsheng Wang; Weiling He
Journal:  Theranostics       Date:  2020-02-10       Impact factor: 11.556

10.  Evaluation of miRNAs Related with Nuclear Factor Kappa B Pathway in Lipopolysaccharide Induced Acute Respiratory Distress Syndrome.

Authors:  Mustafa Azizoğlu; Lokman Ayaz; Gülsen Bayrak; Banu Coşkun Yılmaz; Handan Birbiçer; Nurcan Doruk
Journal:  Int J Mol Cell Med       Date:  2020-08-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.